Individual results vary, and NexLife does not guarantee weight loss, treatment success, clinical outcomes, prescription approval, medication eligibility, pharmacy availability, fulfillment timelines, or delivery outcomes
For compounded semaglutide, 503A pharmacies have until April 22 and 503B facilities have until May 22 or until there is a court decision in the semaglutide case, whichever date comes later
That is the halfway mark on a 1 mL syringe, or the very top line on a 0.5 mL syringe
Among ADMs, semaglutide continues to be the most prescribed medication (1.29% of all prescriptions), although prescription rates decreased (-0.42%)
Tirzepatide is a dual GLP-1 and GIP receptor agonist
Its not a quick fix or fad